Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease

Parkinsonism and Related Disorders

Volumn 20, Issue 12, 2014, Pages 1345-1351

  Giladi, Nir ^a   Ghys, Liesbet ^b   Surmann, Erwin ^b   Boroojerdi, Babak ^b   Jankovic, Joseph ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b UCB PHARMA   (Belgium)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dyskinesia; Levodopa; Parkinson's disease; Rotigotine

Indexed keywords

AMANTADINE; LEVODOPA; PLACEBO; ROTIGOTINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; DISABILITY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSDERMAL DRUG ADMINISTRATION; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84916222281     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.09.016     Document Type: Article

References (31)

1. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005, 20(Suppl.11):S11-S16.
2. Brotchie J., Jenner P. New approaches to therapy. Int Rev Neurobiol 2011, 98:123-150.
3. Pechevis M., Clarke C.E., Vieregge P., Khoshnood B., Deschaseaux-Voinet C., Berdeaux G., et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005, 12:956-963.
4. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
5. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010, 9:1106-1117.
6. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008, 9:665-677.
7. Goto Y., Otani S., Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 2007, 53:583-587.
8. Hauser R.A. New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Parkinsonism Relat Disord 2009, 15(Suppl.3):S17-S21.
9. Jankovic J., Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol 2012, 25(4):433-447.
10. Jenner P. Anovel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005, 65:S3-S5.
11. Scheller D., Ullmer C., Berkels R., Gwarek M., Lübbert H. The invitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009, 379:73-86.
12. Pfeiffer R.F. Apromising new technology for Parkinson's disease. Neurology 2005, 65:S6-S10.
13. Elshoff J.P., Braun M., Andreas J.O., Middle M., Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012, 34:966-978.
14. Schmidt W.J., Lebsanft H., Heindl M., Gerlach M., Gruenblatt E., Riederer P., et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. JNeural Transm 2008, 115:1385-1392.
15. Stockwell K.A., Scheller D., Rose S., Jackson M.J., Tayarani-Binazir K., Iravani M.M., et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol 2009, 219:533-542.
16. Giladi N., Boroojerdi B., Korczyn A.D., Burn D.J., Clarke C.E., Schapira A.H. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-2404.
17. Jankovic J., Watts R.L., Martin W., Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007, 64:676-682.
18. Watts R.L., Jankovic J., Waters C., Rajput A., Boroojerdi B., Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68:272-276.
19. Elmer L.W., Surmann E., Boroojerdi B., Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord 2012, 18:488-493.
20. Giladi N., Boroojerdi B., Surmann E. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease. JNeural Transm 2013, 120:1321-1329.
21. Oertel W., Lewitt P., Giladi N., Ghys L., Grieger F., Boroojerdi B. Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability. Parkinsonism Relat Disord 2013, 19:37-42.
22. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004, 61:1044-1053.
23. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. Afive-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. NEngl J Med 2000, 342:1484-1491.
24. Sharma J.C., Bachmann C.G., Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2010, 16:490-497.
25. Garcia-Ruiz P.J., Del Val J., Fernández I.M., Herranz A. What factors influence motor complications in Parkinson disease?: a 10-year prospective study. Clin Neuropharmacol 2012, 35:1-5.
26. Chillag-Talmor O., Giladi N., Linn S., Gurevich T., El-Ad B., Silverman B., et al. Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach. JNeurol 2013, 260:62-70.
27. Hassin-Baer S., Molchadski I., Cohen O.S., Nitzan Z., Efrati L., Tunkel O., et al. Gender effect on time to levodopa-induced dyskinesias. JNeurol 2011, 258:2048-2053.
28. Arabia G., Zappia M., Bosco D., Crescibene L., Bagala A., Bastone L., et al. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci 2002, 23(Suppl.2):S53-S54.
29. Zappia M., Annesi G., Nicoletti G., Arabia G., Annesi F., Messina D., et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005, 62:601-605.
30. Schrag A., Ben-Shlomo Y., Brown R., Marsden C.D., Quinn N. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998, 13:885-894.
31. Kumar N., Van Gerpen J.A., Bower J.H., Ahlskog J.E. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005, 20:342-344.